Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Is Alzheimer’s disease different in people with Down’s? Two recent proteomics studies say yes. In the July 1 Nature Communications, scientists led by Erik Johnson at Emory University School of ...

Postdoctoral Position- Neurobiology of Parkinson’s Disease JOB 2025-07-09 Employer Université Laval Contact aurelie.jacquet@crchudequebec.ulaval.ca Description The team specializes in the study of ...

As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

The virus–Alzheimer’s tug of war continues. New data across several studies weaken the proposed, and much-debated, association; its proponents are holding fast. Short-term anti-herpes drug use ...

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Several people who received Aβ-contaminated growth hormone in childhood developed dementia in midlife. Four of them had biomarker or pathological evidence of Alzheimer’s disease. This is the first ...

Brain Shuttle Sneaks Gantenerumab Past the Blood-Brain Barrier Initially, gantenerumab was nearly scuttled when low doses failed to budge endpoints in the Phase 3 Scarlet RoAD and Marguerite RoAD ...